earnings
confidence high
sentiment positive
materiality 0.75
Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven
Theravance Biopharma, Inc.
2025-Q3 EPS reported
$0.88
revenue$61,573,000
- YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).
- Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).
- Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.
- Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
- Company achieves non-GAAP breakeven, underscoring financial discipline.